GeoVax Labs (GOVX) Q2 2024 earnings summary

Executive summary

• Secured a BARDA Project NextGen award valued at nearly $400 million to support a 10,000-patient Phase 2b trial for the next-generation COVID-19 vaccine GEO-CM04S1, with Allucent as CRO partner and comparison to an FDA-authorized mRNA vaccine.

• Advanced Gedeptin program with a decision to proceed to a Phase 2 trial in combination with an immune checkpoint inhibitor for squamous cell head and neck cancer, based on positive safety and efficacy data; trial activation anticipated in H1 2025.

• Achieved key milestones in vaccine manufacturing, including first commercial lot of GEO-CM04S1 and technology transfer to Oxford Biomedica.

• Focused on developing innovative cancer therapies and infectious disease vaccines for unmet medical needs, with ongoing business development and partnership initiatives.

• No product revenue to date; operations funded by equity offerings, government contracts, and grants.

Financial highlights

• Reported $301,000 in Q2 2024 revenues from the BARDA contract, with no comparable revenue in 2023.

• Net loss for Q2 2024 was $5.06 million ($1.99/share), down from $5.93 million ($3.79/share) in Q2 2023; six-month net loss was $10.91 million ($4.68/share), compared to $9.97 million ($5.66/share) in 2023.

• Research and development expenses rose to $8.7 million for the first six months of 2024, up 15% year-over-year, mainly due to clinical trial and manufacturing costs.

• General administrative expenses decreased 13% to $2.5 million for the first half of 2024, primarily from lower stock-based compensation and consulting costs.

• Cash balance at June 30, 2024, was $1.56 million, with an additional $2.8 million raised in July not reflected in the Q2 balance sheet.

Outlook and guidance

• BARDA Project NextGen award fully funds the Phase 2b COVID-19 vaccine trial, with total federal support expected between $367 million and $388 million over several years.

• Existing cash is insufficient to fund operations beyond Q3 2024; additional capital is being actively pursued through equity, debt, grants, or partnerships.

• Ongoing non-BARDA clinical programs for Gedeptin and GEO-CM04S1 will require additional fundraising; capital formation plans are in development.

• Multiple clinical data readouts for GEO-CM04S1 expected in the second half of 2024.

• Anticipates continued business development, partnerships, and collaborations to support global commercialization.